Coagulation Analyzers Market to Exhibit Impressive Growth During 2018 – 2024
The global market for coagulation analyzers is anticipated to be worth USD 7.9 billion by the year 2024, advancing at a CAGR of 10.2% during this period, according to a Grand View Research report.
Coagulation analyzers are laboratory instruments capable of measuring blood clotting characteristics. They are used to measure blood prothrombin ratio, which are normally prescribed for patients suffering from unexplained bleeding or thromboses. Coagulation tests can provide diagnostic prevention from potential heart attack-inducing blood clots. The rise in cases of CVDs has created huge opportunities for the coagulation analyzers market.
Various advancements in coagulation analyzers in recent years such as integration of the system with track line systems and work cells, failure pattern sensors that enhance safety and sample integrity, as well as automatic reflex testing, repeat testing and redilution, have also led to increased market attractiveness for them. Moreover, they are able to perform tests such as Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT), D-Dimer, and Fibrinogen, which is a major factor for market growth.
The rise in lifestyle-related and chronic diseases around the globe, such as CVDs and blood disorders, have led to an increased demand for coagulation analyzers in developed as well as emerging economies. Moreover, the prevalence of hemophilia has led to development of various tests that can detect them at the earliest, which again is a positive development for the market. According to the CDC, hemophilia A affects 1 in 5000 male births in the United States, with 400 babies born with this disorder each year. Additionally, data collected from 2012-2018 stated that around 33,000 males in the country were living with hemophilia.
Based on product, the market is segmented into analyzers and consumables. The analyzers segment, which consists of clinical lab analyzers and point of care analyzers, have had a substantial share of the market, with factors such as developing healthcare infrastructure, increased healthcare spending, and the rising prevalence of lifestyle-related diseases leading to accelerated growth. The POC analyzers segment is expected to witness healthy growth, owing to the use of whole blood as sample, no pre-analytical delay and requirement of lesser reagents.
Based on technology, the market has been segmented into mechanical, electrochemical, optical and others. The optical segment, which is further classified into photo optical/chromogenic/immunological, and other patented technologies, is expected to garner the highest market share through the forecast period, owing to the rising combination of immunological, chromogenic techniques with photo optical technique, which has led to development of high performance, multipurpose optical hemostasis analyzers.
Based on test type, the market is segmented into APTT, D-Dimer, Fibrinogen, Prothrombin and others, out of which the prothrombin segment has had a dominant market share followed by APTT, with the latter being majorly used for detecting coagulation inhibitors, Disseminated Intravascular Coagulation (DIC), liver diseases, acquired and inherited abnormalities of the intrinsic coagulation pathway, and monitoring of heparin therapy.
Based on regional analysis, North America led the overall coagulation analyzers market, on account of established healthcare infrastructural presence, along with growing prevalence of cardio metabolic disorders such as Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). The Middle East and Africa region is expected to witness substantial growth in the near future, with a rapidly developing healthcare environment along with presence of skilled professionals aiding regional advancement.
Read More@ https://www.grandviewresearch.com/industry-analysis/coagulation-analyzers-market
Recent Developments
In April 2020, South Korea’s Yongin Severance Hospital introduced an automated blood test, connecting the Cobas t 711 coagulation analyzer, a blood clotting equipment, to Roche Diagnostics’ ‘Cobas connection module (CCM)’, which is a first in the Asia Pacific region. This has been done with a view to conduct more accurate and efficient blood analysis tests by its laboratory medicine.
Instrumentation Laboratory announced the commercial launch of the GEM Premier ChemSTAT in vitro diagnostic (IVD) analyzer with Intelligent Quality Management (iQM) in the United States in March 2020. The GEM Premier ChemSTAT system is a whole-blood analyzer designed for rapid basic metabolic panel (BMP) testing at the point of care, mainly in hospital EDs and Clinical Laboratories.